BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O’connell J, Rowan C, Stack R, Harkin G, Parihar V, Chan G, Breslin N, Cullen G, Dunne C, Egan L, Harewood G, Leyden J, Maccarthy F, Macmathuna P, Mahmud N, Mckiernan S, Mcnamara D, Mulcahy H, Murray F, O’connor A, O’toole A, Patchett S, Ryan B, Sheridan J, Slattery E, Doherty G, Kevans D. Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis. European Journal of Gastroenterology & Hepatology 2018;30:1019-26. [DOI: 10.1097/meg.0000000000001177] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Stefanovic S, Detrez I, Compernolle G, Brouwers E, Sever N, Stabuc B, Smrekar N, Kurent T, Novak G, Kozelj M, Ferrante M, Gils A, Drobne D. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label. Eur J Gastroenterol Hepatol 2021;33:54-61. [PMID: 32804854 DOI: 10.1097/MEG.0000000000001843] [Reference Citation Analysis]
2 Eriksson C, Visuri I, Vigren L, Nilsson L, Kärnell A, Hjortswang H, Bergemalm D, Almer S, Hertervig E, Karlén P, Strid H, Halfvarson J; GO SWIBREG study group. Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG. Scand J Gastroenterol 2021;56:1304-11. [PMID: 34415803 DOI: 10.1080/00365521.2021.1963466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Cunningham G, Samaan MA, Irving PM. Golimumab in the treatment of ulcerative colitis. Therap Adv Gastroenterol 2019;12:1756284818821266. [PMID: 30728858 DOI: 10.1177/1756284818821266] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]